| HOME >> BIOLOGY >> TECHNOLOGY |
Other assets 68,854 71,148
Total assets $9,059,863 $11,324,323
LIABILITIES AND SHAREHOLDERS' DEFICIT
Current liabilities
Accounts payable $2,178,068 $2,134,256
Accrued expenses 4,296,348 4,511,775
Deferred revenue 485,786 547,286
Notes payable - current 6,725,374 6,671,112
Total current liabilities 13,685,576 13,864,429
Deferred rent 18,856 21,426
Note payable - long term 2,491,199 2,943,432
Total liabilities 16,195,631 16,829,287
Commitments and contingencies
Shareholders' deficit
Preferred stock ($0.001 par value)
5,000,000 shares authorized; none
issued and outstanding - -
Common stock ($0.001 par value) 50,000,000
shares authorized; 14,447,138 and
13,347,138 shares issued and
outstanding as of March 31, 2008
and December 31, 2007, respectively 14,447 13,347
Additional paid-in capital 78,720,440 77,061,296
Deficit accumulated during the
development stage (85,870,655) (82,579,607)
Total shareholders' deficit (7,135,768) (5,504,964)
Total liabilities and shareholders'
deficit $9,059,863 $11,324,323
Bioheart, Inc. and Subsidiaries
Consolidated Statements of Operations
For the Three-Month Period
'/>"/>
| SOURCE Bioheart, Inc. Copyright©2008 PR Newswire. All rights reserved |